Literature DB >> 11557458

Enhancement of fluoroquinolone activity by C-8 halogen and methoxy moieties: action against a gyrase resistance mutant of Mycobacterium smegmatis and a gyrase-topoisomerase IV double mutant of Staphylococcus aureus.

T Lu1, X Zhao, X Li, A Drlica-Wagner, J Y Wang, J Domagala, K Drlica.   

Abstract

The increasing prevalence of antibiotic resistance among bacterial pathogens prompted a microbiological study of fluoroquinolone structure-activity relationships with resistant mutants. Bacteriostatic and bactericidal activities for 12 fluoroquinolones were examined with a gyrase mutant of Mycobacterium smegmatis and a gyrase-topoisomerase IV double mutant of Staphylococcus aureus. For both organisms C-8 halogen and C-8 methoxy groups enhanced activity. The MIC at which 99% of the isolates tested were inhibited (MIC(99)) was reduced three- to fivefold for the M. smegmatis mutant and seven- to eightfold for the S. aureus mutant by C-8 bromine, chlorine, and methoxy groups. With both organisms a smaller reduction in the MIC(99) (two- to threefold) was associated with a C-8 fluorine moiety. In most comparisons with M. smegmatis the response to a C-8 substituent was similar (within twofold) for wild-type and mutant cells. In contrast, mutant S. aureus was affected more than the wild type by the addition of a C-8 substituent. C-8 halogen and methoxy groups also improved the ability to kill the two mutants and the respective wild-type cells when measured with various fluoroquinolone concentrations during an incubation period equivalent to four to five doubling times. Collectively these data help define a group of fluoroquinolones that can serve (i) as a base for structure refinement and (ii) as test compounds for slowing the development of fluoroquinolone resistance during infection of vertebrate hosts.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11557458      PMCID: PMC90720          DOI: 10.1128/AAC.45.10.2703-2709.2001

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  30 in total

1.  Selection of antibiotic-resistant bacterial mutants: allelic diversity among fluoroquinolone-resistant mutations.

Authors:  J Zhou; Y Dong; X Zhao; S Lee; A Amin; S Ramaswamy; J Domagala; J M Musser; K Drlica
Journal:  J Infect Dis       Date:  2000-07-24       Impact factor: 5.226

Review 2.  Genetic systems for mycobacteria.

Authors:  W R Jacobs; G V Kalpana; J D Cirillo; L Pascopella; S B Snapper; R A Udani; W Jones; R G Barletta; B R Bloom
Journal:  Methods Enzymol       Date:  1991       Impact factor: 1.600

3.  Interaction between DNA gyrase and quinolones: effects of alanine mutations at GyrA subunit residues Ser(83) and Asp(87).

Authors:  F M Barnard; A Maxwell
Journal:  Antimicrob Agents Chemother       Date:  2001-07       Impact factor: 5.191

4.  Studies on plasmid replication. I. Plasmid incompatibility and establishment in Staphylococcus aureus.

Authors:  R P Novick; R Brodsky
Journal:  J Mol Biol       Date:  1972-07-21       Impact factor: 5.469

5.  Gatifloxacin activity against quinolone-resistant gyrase: allele-specific enhancement of bacteriostatic and bactericidal activities by the C-8-methoxy group.

Authors:  T Lu; X Zhao; K Drlica
Journal:  Antimicrob Agents Chemother       Date:  1999-12       Impact factor: 5.191

6.  Quinolone resistance-determining region in the DNA gyrase gyrA gene of Escherichia coli.

Authors:  H Yoshida; M Bogaki; M Nakamura; S Nakamura
Journal:  Antimicrob Agents Chemother       Date:  1990-06       Impact factor: 5.191

7.  Mechanisms and frequency of resistance to premafloxacin in Staphylococcus aureus: novel mutations suggest novel drug-target interactions.

Authors:  D Ince; D C Hooper
Journal:  Antimicrob Agents Chemother       Date:  2000-12       Impact factor: 5.191

8.  Mutant prevention concentration as a measure of fluoroquinolone potency against mycobacteria.

Authors:  G Sindelar; X Zhao; A Liew; Y Dong; T Lu; J Zhou; J Domagala; K Drlica
Journal:  Antimicrob Agents Chemother       Date:  2000-12       Impact factor: 5.191

9.  Antimicrobial resistance of Shigella isolates in Bangladesh, 1983-1990: increasing frequency of strains multiply resistant to ampicillin, trimethoprim-sulfamethoxazole, and nalidixic acid.

Authors:  M L Bennish; M A Salam; M A Hossain; J Myaux; E H Khan; J Chakraborty; F Henry; C Ronsmans
Journal:  Clin Infect Dis       Date:  1992-05       Impact factor: 9.079

10.  Purification and inhibition by quinolones of DNA gyrases from Mycobacterium avium, Mycobacterium smegmatis and Mycobacterium fortuitum bv. peregrinum.

Authors:  Isabelle Guillemin; Wladimir Sougakoff; Emmanuelle Cambau; Valérie Revel-Viravau; Nicole Moreau; Vincent Jarlier
Journal:  Microbiology       Date:  1999-09       Impact factor: 2.777

View more
  17 in total

1.  Selection of Streptococcus pneumoniae mutants having reduced susceptibility to moxifloxacin and levofloxacin.

Authors:  Xinying Li; Xilin Zhao; Karl Drlica
Journal:  Antimicrob Agents Chemother       Date:  2002-02       Impact factor: 5.191

2.  Contribution of the C-8-methoxy group of gatifloxacin to inhibition of type II topoisomerases of Staphylococcus aureus.

Authors:  Masaya Takei; Hideyuki Fukuda; Ryuta Kishii; Youko Kadowaki; Yukiko Atobe; Masaki Hosaka
Journal:  Antimicrob Agents Chemother       Date:  2002-10       Impact factor: 5.191

Review 3.  How antibiotics kill bacteria: from targets to networks.

Authors:  Michael A Kohanski; Daniel J Dwyer; James J Collins
Journal:  Nat Rev Microbiol       Date:  2010-05-04       Impact factor: 60.633

4.  Comparative mutant prevention concentrations of pradofloxacin and other veterinary fluoroquinolones indicate differing potentials in preventing selection of resistance.

Authors:  H-G Wetzstein
Journal:  Antimicrob Agents Chemother       Date:  2005-10       Impact factor: 5.191

5.  Suppression of Reactive Oxygen Species Accumulation Accounts for Paradoxical Bacterial Survival at High Quinolone Concentration.

Authors:  Gan Luan; Yuzhi Hong; Karl Drlica; Xilin Zhao
Journal:  Antimicrob Agents Chemother       Date:  2018-02-23       Impact factor: 5.191

6.  Fluoroquinolone resistance in Streptococcus pneumoniae: area under the concentration-time curve/MIC ratio and resistance development with gatifloxacin, gemifloxacin, levofloxacin, and moxifloxacin.

Authors:  Kerry L LaPlante; Michael J Rybak; Brian Tsuji; Thomas P Lodise; Glenn W Kaatz
Journal:  Antimicrob Agents Chemother       Date:  2007-02-12       Impact factor: 5.191

7.  Use of gyrase resistance mutants to guide selection of 8-methoxy-quinazoline-2,4-diones.

Authors:  Nadezhda German; Muhammad Malik; Jonathan D Rosen; Karl Drlica; Robert J Kerns
Journal:  Antimicrob Agents Chemother       Date:  2008-09-02       Impact factor: 5.191

8.  Activities of mutant prevention concentration-targeted moxifloxacin and levofloxacin against Streptococcus pneumoniae in an in vitro pharmacodynamic model.

Authors:  George P Allen; Glenn W Kaatz; Michael J Rybak
Journal:  Antimicrob Agents Chemother       Date:  2003-08       Impact factor: 5.191

9.  Relationships among ciprofloxacin, gatifloxacin, levofloxacin, and norfloxacin MICs for fluoroquinolone-resistant Escherichia coli clinical isolates.

Authors:  Lauren Becnel Boyd; Merry J Maynard; Sonia K Morgan-Linnell; Lori Banks Horton; Richard Sucgang; Richard J Hamill; Javier Rojo Jimenez; James Versalovic; David Steffen; Lynn Zechiedrich
Journal:  Antimicrob Agents Chemother       Date:  2008-10-06       Impact factor: 5.191

10.  Multiplex PCR amplimer conformation analysis for rapid detection of gyrA mutations in fluoroquinolone-resistant Mycobacterium tuberculosis clinical isolates.

Authors:  Augustine F B Cheng; Wing W Yew; Edward W C Chan; Miu L Chin; Mamie M M Hui; Raphael C Y Chan
Journal:  Antimicrob Agents Chemother       Date:  2004-02       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.